HIV Drugs Market - By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Others ) By Application (Hospital Pharmacies, Retail Pharmacies, Others) By Administration (Oral, Parenteral) And By Region, Opportunities And Strategies – Global Forecast To 2030

Starting Price : $4000 | Pages : 234 | Published : May 2021 | SKU CODE : o&s241 | Format :

Request Sample

HIV Drugs Market Definition

The HIV drug market consists of sales of human immunodeficiency virus (HIV) drugs used for the treatment of HIV infection. The market consists of revenue generated by the anti-retroviral (ARV) drug companies manufacturing anti-retroviral drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs) for the treatment of a HIV infection.

HIV Drugs Market Size

The global HIV drugs market reached a value of nearly $30,520.0 million in 2020, having increased at a compound annual growth rate (CAGR) of 8.1% since 2015.  The market is expected to grow from $30,520.0 million in 2020 to $36,460.0 million in 2025 at a rate of 3.6%. The growth is mainly due to the growing prevalence of HIV and government initiatives which is expected to drive the demand for HIV drugs. The market is expected to grow from $36,460.0 million in 2025 to $40,303.1 million in 2030 at a CAGR of 2.0%.  

Growth in the historic period resulted from increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets. This growth was restricted by challenges due to regulatory changes, patent expiration of drugs, rise in alternative medications and low healthcare access.

Going forward, government initiatives, cheaper interest rates, development in drug discovery and cheaper interest rates will support the market growth. Side effects of HIV drugs, shortage of supply of HIV drugs, impact of COVID-19 and low rate of voluntary screening are major factors that could hinder the growth of the HIV drugs market in the future.

HIV Drugs Market Drivers

The key drivers of the HIV drugs market include:

Government Initiatives

Government initiatives and efforts towards implementing reforms have had a significant impact on the market, in both developed and developing countries. For instance, the Health Resources and Services Administration’s (HRSA) Bureau of Primary Health Care announced the availability of around $83 million for up to 300 health centers for the fiscal year 2021 Ending the HIV Epidemic- Primary Care HIV Prevention (PCHP) program. The PCHP funding is likely to expand HIV prevention services with the motive of decreasing the risk of HIV transmission across 57 geographic locations recognized by Ending the HIV Epidemic: A Plan for America.  Additionally, in December 2020, the fiscal year budget passed included $386 million for the implementation of the EHE initiative along with $175 million for the Centers for Disease Control and Prevention (CDC) to reduce new HIV infections.   Therefore, these government initiatives push the development of HIV drug demand and thereby contributing to the growth of the market in the forecast period.

HIV Drugs Market Restraints

The key restraints on the HIV drugs market include:

Coronavirus Pandemic

The outbreak of Coronavirus disease (COVID-19) has acted as a significant restraint on the HIV drug market in 2020 as supply chains were disrupted due to restrictions on the trade of pharmaceutical ingredients and products across countries. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and spread globally including Western Europe, North America, and Asia. Various steps taken by national governments to contain the spread of virus have resulted in a decline in economic activity with countries entering a state of 'lockdown' and the outbreak is expected to continue to hinder businesses throughout 2020 and into 2021. Pharmaceutical markets such as this one has been relatively less impacted however due to the continued availability of drugs during government lockdowns and inelasticity of demand. It is expected that the HIV drugs market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy.

HIV Drugs Market Trends

Major trends influencing the HIV drugs market include:

Multi-Class Combination Products For HIV Treatment

Companies operating in the HIV drugs market are increasingly focusing on the development and launch of multi-class combination for treatment of retroviral infections. Combination drugs combine multiple medications into one drug form. Multi-class combination drugs or single-tablet regimens (STRs), include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). Multi-class combination products are gaining significant popularity attributing to rising burden of HIV. For instance, in December 2019, Hetero, an India-based pharmaceutical company launched an anti-retroviral combination drug consisting a combination of drugs including Bictegravir (50mg), Emtricitabine (200mg), and Tenofovir Alafenamide (25mg) for treating patients with HIV.

3D Bioprinting Technology

HIV drug manufacturing companies are increasingly adopting 3D bioprinting technology in the development and manufacturing processes of HIV drugs to reduce manufacturing costs and increase production efficiencies and expedite the process of drug discovery. 3D bioprinting is a manufacturing process where a 3D structure of the tissue is created using bio-ink. Bio-inks are materials which are used to produce artiificial live tissues using 3D printing. For instance, Viiv Healthcare Limited, a USA-based pharmaceutical company specializing in developing HIV therapies is using HP's D300 for creating latency reversal drugs for HIV. Moreover, companies are continuously manufacturing 3D bioprinters for overcoming technical limitations plaguing pharmaceutical research, regenerative medicine, and tissue engineering. For example, in December 2020, mimiX Biotherapeutics, a biotechnology company launched cymatiX, the company’s first acoustic bioprinter intended for an affordable and fast method of fabricating multi-cellular tissue constructs.

Opportunities And Recommendations In The HIV Drugs Market

Opportunities –The top opportunities in the HIV drugs market segmented by type will arise in the non-nucleoside reverse transcriptase inhibitors segment, which will gain $6,152 million of global annual sales by 2025. The top opportunities in the HIV drugs market segmented by route of administration will arise in the oral segment, which will gain $5,692.8 million of global annual sales by 2025. The top opportunities in the HIV drugs market segmented by application will arise in the hospital pharmacies segment, which will gain $3,175.7 million of global annual sales by 2025. The HIV drugs’ market size will gain the most in the USA at $2,466 million. Market-trend-based strategies for the HIV drugs market include investing in 3D bioprinting technology, new product innovations, developing multi-class combination products for HIV treatment and investing in strategic collaborations and agreements. Player-adopted strategies in the HIV drugs market include investing in expanding operations through innovative product launches, investing in collaborations and mergers and getting approvals for new drugs for HIV treatment.

Recommendations –To take advantage of the opportunities, The Business Research Company recommends the HIV drug companies to focus on the use of automation, focus on combination therapy, focus on research and development of innovative products, focus on collaborations, expand in markets with high incidence of HIV, provide competitively priced offerings, premium pricing for innovative drugs, companies should focus on increasing awareness on HIV infection, companies should leverage e-commerce tools to maximize reach, focus on uneducated population and target young population.

China; India; Japan; Australia; Indonesia; South Korea; USA; Brazil; UK; Germany; France; Russia

HIV Drugs Market Segmentation

The HIV drugs market is segmented by type, by application, by administration and by geography.

By Type -

The HIV drugs market is segmented by type into
    • a) Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
    • b) Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
    • c) Protease Inhibitors
    • d) Integrase strand transfer inhibitors (INSTIs)
    • e) Others
The non-nucleoside reverse transcriptase inhibitors were the largest segment of the HIV drugs market by type, accounting for 29.4% of the total market in 2020. Going forward, it is also is expected to be the fastest growing segment in the HIV drugs market, at a CAGR of 11.1% during 2020-2025.

By Application-

The HIV drugs market is further segmented by application into
    • a) Hospital Pharmacies
    • b) Retail Pharmacies
    • c) Others
The hospital pharmacy was the largest segment of the HIV drugs market by application, accounting for 64.6% of the total market in 2020. Going forward, the others segment is expected to be the fastest growing segment in the HIV drugs market, at a CAGR of 5.4%, during 2020-2025.

By Administration-

The HIV drugs market is further segmented by administration into
    • a) Oral
    • b) Parenteral
The oral was the largest segment of the HIV drugs market by route of administration, accounting for 94.5% of the total market in 2020. Going forward, it is also expected to the fastest growing segment in the HIV drugs market, at a CAGR of 3.7%.

By Geography-

The industrial machinery market is segmented by geography into
    • o North America
    • • USA
    o Western Europe
    • • UK
    • • Germany
    • • France
    o Asia Pacific
    • • China
    • • Japan
    • • India
    • • Australia
    • • Indonesia
    • • South Korea
    o Eastern Europe
    • • Russia
    o South America
    • • Brazil
    o Middle East
    o Africa
North America was the largest region in the global HIV drugs market, accounting for 51.1% of the total in 2020. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the HIV drugs market will be Africa and Asia-Pacific, where growth will be at CAGRs of 6.0% and 4.1% respectively. These will be followed by Middle East and North America, where the markets are expected to register CAGRs of 4.9% and 3.5% respectively.

HIV Drugs Competitive Landscape

Major Competitors are:

  • • Gilead Sciences, Inc.
  • • GlaxoSmithKline plc.
  • • Johnson & Johnson
  • • Merck & Co., Inc.
  • • Boehringer Ingelheim International GmbH

Other Competitors Include:

  • • Cipla
  • • Aurobindo Pharma
  • • AbbVie
  • • Aspen Pharmacare Limited
  • • Pharmacare Ltd.
  • • Zion Medical
  • • Pfizer
  • • Abbott Laboratories
  • • Alfa Rio Química Ltda.
  • • Globe Quimica S/A
  • • Nortec Química S.A.
  • • Microbiológica Química e Farmacêutica
  • • Indústria e Comércio de Medicamentos Labogen S.A.
  • • AstraZeneca
  • • Gritstone Oncology
  • • Enzolytics Inc.
  • • BioClonetics Immunotherapeutics, Inc.
  • • Dewpoint Therapeutics
  • • ViiV Healthcare
  • • Lyndra Therapeutics
  • • Mylan N.V.
  • • Bristol-Myers Squibb Company
  • • F. Hoffmann-La Roche AG
  • • Teva Canada
  • • Pharmstandard
  • • Pharmasyntez
  • • R-Pharm
  • • Alium
  • • ChemRar Group
  • • CytoDyn Inc.
  • • Janssen Pharmaceutical
  • • Bavarian Nordic
  • • Emcure Pharmaceuticals
  • • Micro Labs Limited
  • • Shanghai Desano Bio Pharmaceutical
  • • Northeast Pharmaceutical Group Co. Ltd
  • • Dr. Reddy's Laboratories Ltd.
  • • Sun Pharmaceutical Industries Ltd
  • • Strides Arcolab Limited
  • • Hetero labs limited

    1. HIV Drugs Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction

    7. Segmentation By Geography

    7.1 Segmentation By Type

    7.2 Segmentation By Application

    7.3 Segmentation By Administration

    8. HIV Drugs Market Characteristics

    8.1 Market Definition

    8.2 Market Segmentation By Type

    8.2.1 Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

    8.2.2 Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

    8.2.3 Protease Inhibitors

    8.2.4 Integrase strand transfer inhibitors (INSTIs)

    8.2.5 Others

    8.3 Market Segmentation By Application

    8.3.1 Hospital Pharmacies

    8.3.2 Retail Pharmacies

    8.3.3 Others

    8.4 Market Segmentation By Administration

    8.4.1 Oral

    8.4.2 Parenteral

    9 HIV Drugs Market Trends And Strategies

    9.1 Multi-Class Combination Products For HIV Treatment

    9.2 3D Bioprinting Technology

    9.3 Increasing Number Of Pipeline Studies And Drug Development

    9.4 Global Research Initiatives And Funding

    9.5 New Product Innovations

    9.6 Strategic Collaborations And Agreements

    10 Impact Of COVID-19 On The HIV Drugs Market

    10.1 Consumer Perception

    10.2 High Mortality Among HIV/AIDS Patients

    10.3 COVID-19 Impact On HIV Treatment

    10.4 High Demand for HIV And Anti-viral Drugs During COVID-19 Outbreak

    10.5 Conclusion

    11 Global HIV Drugs Market Size And Growth

    11.1 Market Size

    11.2 Historic Market Growth, 2015 – 2020, Value ($ Million)

    11.2.1 Drivers Of The Market 2015 – 2020

    11.2.2 Restraints On The Market 2015 – 2020

    11.3 Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    11.3.1 Drivers Of The Market 2020 – 2025

    11.3.2 Restraints On The Market 2020 – 2025

    12 Global HIV Drugs Market Segmentation

    12.1 Global HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    12.1.1 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

    12.1.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

    12.1.3 Integrase Strand Transfer Inhibitors (INSTIs)

    12.1.4 Protease Inhibitors (PIs)

    12.1.5 Others

    12.2 Global HIV Drugs Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    12.2.1 Hospital Pharmacies

    12.2.2 Retail Pharmacies

    12.2.3 Others

    12.3 Global HIV Drugs Market, Segmentation By Administration, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    12.3.1 Oral

    12.3.2 Parenteral

    13 HIV Drugs Market, Regional And Country Analysis

    13.1 Global HIV Drugs Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.2 Global HIV Drugs Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14 Asia-Pacific HIV Drugs Market

    14.1 Asia-Pacific HIV Drugs Market Overview

    14.1.1 Region Information

    14.1.2 Market Information

    14.1.3 COVID-19 Impact

    14.1.4 Background Information

    14.1.5 Government Initiatives

    14.1.6 Regulations

    14.1.7 Regulatory Bodies

    14.1.8 Major Associations

    14.1.9 Taxes levied

    14.1.10 Corporate Tax Structure

    14.1.11 Investments

    14.1.12 Major Companies

    14.2 Asia-Pacific HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.3 Asia-Pacific HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.4 Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.5 Asia-Pacific HIV Drugs Market: Country Analysis

    14.6 China HIV Drugs Market

    14.7 China HIV Drugs Market Overview

    14.7.1 Country Information

    14.7.2 Market Information

    14.7.3 COVID-19 Impact

    14.7.4 Background Information

    14.7.5 Government Initiatives

    14.7.6 Regulations

    14.7.7 Regulatory Bodies

    14.7.8 Major Associations

    14.7.9 Taxes levied

    14.7.10 Corporate Tax Structure

    14.7.11 Investments

    14.7.12 Major Companies

    14.8 China HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.9 China HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.10 China HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.11 India HIV Drugs Market

    14.12 India HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.13 India HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.14 India HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.15 Japan HIV Drugs Market

    14.16 Japan HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.17 Japan HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.18 Japan HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.19 Australia HIV Drugs Market

    14.20 Australia HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.21 Australia HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.22 Australia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.23 Indonesia HIV Drugs Market

    14.24 Indonesia HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.25 Indonesia HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.26 Indonesia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.27 South Korea HIV Drugs Market

    14.28 South Korea HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.29 South Korea HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.30 South Korea HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15 Western Europe HIV Drugs Market

    15.1 Western Europe HIV Drugs Market Overview

    15.1.1 Region Information

    15.1.2 Market Information

    15.1.3 COVID-19 Impact

    15.1.4 Background Information

    15.1.5 Government Initiatives

    15.1.6 Regulations

    15.1.7 Regulatory Bodies

    15.1.8 Major Associations

    15.1.9 Taxes levied

    15.1.10 Corporate Tax Structure

    15.1.11 Investments

    15.1.12 Major Companies

    15.2 Western Europe HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    15.3 Western Europe HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.4 Western Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15.5 Western Europe HIV Drugs Market: Country Analysis

    15.6 UK HIV Drugs Market

    15.7 UK HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    15.8 UK HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.9 UK HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15.10 Germany HIV Drugs Market

    15.11 Germany HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    15.12 Germany HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.13 Germany HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15.14 France HIV Drugs Market

    15.15 France HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    15.16 France HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.17 France HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    16 Eastern Europe HIV Drugs Market

    16.1 Eastern Europe HIV Drugs Market Overview

    16.1.1 Region Information

    16.1.2 Market Information

    16.1.3 COVID-19 Impact

    16.1.4 Background Information

    16.1.5 Government Initiatives

    16.1.6 Regulations

    16.1.7 Regulatory Bodies

    16.1.8 Tax Levied

    16.1.9 Major Associations

    16.1.10 Corporate Tax Structure

    16.1.11 Investments

    16.1.12 Major Companies

    16.2 Eastern Europe HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    16.3 Eastern Europe HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    16.4 Eastern Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    16.5 Eastern Europe HIV Drugs Market: Country Analysis

    16.6 Russia HIV Drugs Market

    16.7 Russia HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    16.8 Russia HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    16.9 Russia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    17 North America HIV Drugs Market

    17.1 North America HIV Drugs Market Overview

    17.1.1 Region Information

    17.1.2 Market Information

    17.1.3 COVID-19 Impact

    17.1.4 Background Information

    17.1.5 Government Initiatives

    17.1.6 Regulations

    17.1.7 Regulatory Bodies

    17.1.8 Major Associations

    17.1.9 Taxes levied

    17.1.10 Corporate Tax Structure

    17.1.11 Investments

    17.1.12 Major Companies

    17.2 North America HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    17.3 North America HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    17.4 North America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    17.5 North America HIV Drugs Market: Country Analysis

    17.6 USA HIV Drugs Market

    17.6.1 USA HIV Drugs Market Overview

    17.6.2 Country Information

    17.6.3 Market Information

    17.6.4 COVID-19 Impact

    17.6.5 Background Information

    17.6.6 Government Initiatives

    17.6.7 Regulations

    17.6.8 Regulatory Bodies

    17.6.9 Major Associations

    17.6.10 Corporate Tax Structure

    17.6.11 Investments

    17.6.12 Major Companies

    17.7 USA HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    17.8 USA HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    17.9 USA HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    18 South America HIV Drugs Market

    18.1 South America HIV Drugs Market Overview

    18.1.1 Region Information

    18.1.2 Market Information

    18.1.3 COVID-19 Impact

    18.1.4 Background Information

    18.1.5 Government Initiatives

    18.1.6 Regulations

    18.1.7 Regulatory Bodies

    18.1.8 Tax Levied

    18.1.9 Major Associations

    18.1.10 Corporate Tax Structure

    18.1.11 Investments

    18.1.12 Major Companies

    18.2 South America HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    18.3 South America HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    18.4 South America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    18.5 South America HIV Drugs Market: Country Analysis

    18.6 Brazil HIV Drugs Market

    18.7 Brazil HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    18.8 Brazil HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    18.9 Brazil HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    19 Middle East HIV Drugs Market

    19.1 Middle East HIV Drugs Market Overview

    19.1.1 Region Information

    19.1.2 Market Information

    19.1.3 COVID-19 Impact

    19.1.4 Background Information

    19.1.5 Government Initiatives

    19.1.6 Regulations

    19.1.7 Regulatory Bodies

    19.1.8 Major Associations

    19.1.9 Taxes Levied

    19.1.10 Corporate Tax Structure

    19.1.11 Investment

    19.1.12 Major Companies

    19.2 Middle East HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    19.3 Middle East HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    19.4 Middle East HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    20 Africa HIV Drugs Market

    20.1 Africa HIV Drugs Market Overview

    20.1.1 Region Information

    20.1.2 Market Information

    20.1.3 COVID-19 Impact

    20.1.4 Background Information

    20.1.5 Government Initiatives

    20.1.6 Regulations

    20.1.7 Regulatory Bodies

    20.1.8 Major Associations

    20.1.9 Taxes Levied

    20.1.10 Corporate Tax Structure

    20.1.11 Investments

    20.1.12 Major Companies

    20.2 Africa HIV Drugs Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    20.3 Africa HIV Drugs Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    20.4 Africa HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    21 Global HIV Drugs Market Competitive Landscape

    21.1 Company Profiles

    21.2 Gilead Sciences, Inc.

    21.2.1 Company Overview

    21.2.2 Products And Services

    21.2.3 Business Strategy

    21.2.4 Financial Overview

    21.3 GlaxoSmithKline

    21.3.1 Company Overview

    21.3.2 Products And Services

    21.3.3 Business Strategy

    21.3.4 Financial Overview

    21.4 Johnson & Johnson

    21.4.1 Company Overview

    21.4.2 Products And Services

    21.4.3 Business Strategy

    21.4.4 Financial Overview

    21.5 Merck & Co., Inc.

    21.5.1 Company Overview

    21.5.2 Products And Services

    21.5.3 Business Strategy

    21.5.4 Financial Overview

    21.6 Boehringer Ingelheim International GmbH

    21.6.1 Company Overview

    21.6.2 Products And Services

    21.6.3 Financial Overview

    22 Key Mergers And Acquisitions In The HIV Drugs Market

    22.1 Gilead Sciences Partnered With Gritstone Oncology

    22.2 Beximco Pharmaceuticals Acquired Stakes in Sanofi Bangladesh

    22.3 CytoDyn Inc. Collaborates With amfAR

    22.4 Merck Partnered With Dewpoint Therapeutics

    22.5 ViiV Healthcare Collaborated With Chapel Hill

    22.6 HOOKIPA Pharma Inc. Partners With Gilead Sciences

    22.7 Lyndra Therapeutics Collaborates With Gilead Sciences

    22.8 Mylan Acquired Ascendis Health

    22.9 Mylan Collaborate With Atomo Diagnostics

    22.10 ViiV Healthcare To Collaborate With Janssen

    23 HIV Drugs Market Opportunities And Strategies

    23.1 Global HIV Drugs Market In 2025 – Countries Offering Most New Opportunities

    23.2 Global HIV Drugs Market In 2025 – Segments Offering Most New Opportunities

    23.3 Global HIV Drugs Market In 2025 – Growth Strategies

    23.3.1 Market Trend Based Strategies

    23.3.2 Competitor Strategies

    24 HIV Drugs Market Conclusions And Recommendations

    24.1 Conclusions

    24.2 Recommendations

    24.2.1 Product

    24.2.2 Place

    24.2.3 Price

    24.2.4 Promotion

    24.2.5 People

    25 Appendix

    25.1.1 Market Data Sources

    25.1.2 Research Methodology

    25.1.3 Currencies

    25.1.4 Research Inquiries

    25.1.5 The Business Research Company

    25.1.6 Copyright and Disclaimer

List Of Tables

    Table 1: Global HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 2: Global HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 3: Global HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 4: Global HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 5: Global HIV Drugs Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 6: Global HIV Drugs Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 7: Global HIV Drugs Market, Segmentation By Administration, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 8: Global HIV Drugs Market, Segmentation By Administration, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 9: Global HIV Drugs Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 10: Global HIV Drugs Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 11: Global HIV Drugs Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 12: Global HIV Drugs Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 13:  Asia Pacific Population By Age Group, 2015-2025, Thousands
  • Table 14: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 15: Asia Pacific GDP Per Capita, 2015-2019, $
  • Table 16: Asia Pacific HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 17: Asia-Pacific HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 18: Asia-Pacific HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 19: Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 20: Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 21:  China Population By Age Group, 2015-2025, Thousands
  • Table 22: China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 23: China GDP Per Capita, 2015-2019, $
  • Table 24: China HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 25: China HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 26: China HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 27: China HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 28: China HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 29: India HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 30: India HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 31: India HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 32: India HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 33: Japan HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 34: Japan HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 35: Japan HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 36: Japan HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 37: Australia HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 38: Australia HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 39: Australia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 40: Australia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 41: Indonesia HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 42: Indonesia HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 43: Indonesia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 44: Indonesia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 45: South Korea HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 46: South Korea HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 47: South Korea HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 48: South Korea HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 49:  Western Europe Population By Age Group, 2015-2025, Thousands
  • Table 50: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 51: Western Europe GDP Per Capita, 2015-2019, $
  • Table 52: Western Europe HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 53: Western Europe HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 54: Western Europe HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 55: Western Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 56: Western Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 57: UK HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 58: UK HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 59: UK HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 60: UK HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 61: Germany HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 62: Germany HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 63: Germany HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 64: Germany HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 65: France HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 66: France HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 67: France HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 68: France HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 69:  Eastern Europe Population By Age Group, 2015-2025, Thousands
  • Table 70: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 71: Eastern Europe GDP Per Capita, 2015-2019, $
  • Table 72: Eastern Europe HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 73: Eastern Europe HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 74: Eastern Europe HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 75: Eastern Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 76: Eastern Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 77: Russia HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 78: Russia HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 79: Russia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 80: Russia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 81:  North America Population By Age Group, 2015-2025, Thousands
  • Table 82: North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 83: North America GDP Per Capita, 2015-2019, $
  • Table 84: North America HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 85: North America HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 86: North America HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 87: North America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 88: North America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 89:  USA Population By Age Group, 2015-2025, Thousands
  • Table 90: USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 91: USA GDP Per Capita, 2015-2019, $
  • Table 92: USA HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 93: USA HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 94: USA HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 95: USA HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 96: USA HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 97:  South America Population By Age Group, 2015-2025, Thousands
  • Table 98: South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 99: South America GDP Per Capita, 2015-2019, $
  • Table 100: South America HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 101: South America HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 102: South America HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 103: South America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 104: South America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 105: Brazil HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 106: Brazil HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 107: Brazil HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 108: Brazil HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 109:  Middle East Population By Age Group, 2015-2025, Thousands
  • Table 110: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 111: Middle East GDP Per Capita, 2015-2019, $
  • Table 112: Middle East HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 113: Middle East HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 114: Middle East HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 115: Middle East HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 116: Middle East HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 117:  Africa Population By Age Group, 2015-2025, Thousands
  • Table 118: Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 119: Africa GDP Per Capita, 2015-2019, $
  • Table 120: Africa HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 121: Africa HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Table 122: Africa HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 123: Africa HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 124: Africa HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 125: Global HIV Drugs Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 126: Gilead Sciences, Inc. –  Financial Performance, 2015 – 2019, $ Billion
  • Table 127: GlaxoSmithKline Plc.  –  Financial Performance, 2015 – 2019, $ Billion
  • Table 128: Johnson & Johnson (J&J) – Financial Performance, 2015 – 2019, $ Billion
  • Table 129: Merck & Co. – Financial Performance, 2015-2019, $ Billion
  • Table 130: Boehringer Ingelheim GmbH – Financial Performance, 2015 - 2019, $ Billion
  • Table 131: Global HIV Drugs Market Size Gain ($ Million), 2020 – 2025, By Country
  • Table 132: Global HIV Drugs Market Size Gain ($ Million), Segmentation By Type, 2020 – 2025
  • Table 133: Global HIV Drugs Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025
  • Table 134: Global HIV Drugs Market Size Gain ($ Million), Segmentation By Administration, 2020 – 2025
  • Table 135: HIV Drugs - Market Data Sources

List Of Figures

    Figure 1: Global HIV Drugs Market Segmentation By Type
  • Figure 2: Global HIV Drugs Market Segmentation By Application
  • Figure 3: Global HIV Drugs Market Segmentation By Administration
  • Figure 4: Global HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 5: Global HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 6: Global HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 7: Global HIV Drugs Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 8: Global HIV Drugs Market, Segmentation By Administration, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 9: Global HIV Drugs Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 10: Global HIV Drugs Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 11: Asia-Pacific HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 12: Asia-Pacific HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 13: Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 14: China HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 15: China HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 16: China HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 17: India HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 18: India HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 19: India HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 20: Japan HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 21: Japan HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 22: Japan HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 23: Australia HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 24: Australia HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 25: Australia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 26: Indonesia HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 27: Indonesia HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 28: Indonesia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 29: South Korea HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 30: South Korea HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 31: South Korea HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 32: Western Europe HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 33: Western Europe HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 34: Western Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 35: UK HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 36: UK HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 37: UK HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 38: Germany HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 39: Germany HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 40: Germany HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 41: France HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 42: France HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 43: France HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 44: Eastern Europe HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 45: Eastern Europe HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 46: Eastern Europe HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 47: Russia HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 48: Russia HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 49: Russia HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 50: North America HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 51: North America HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 52: North America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 53: USA HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 54: USA HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 55: USA HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 56: South America HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 57: South America HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 58: South America HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 59: Brazil HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 60: Brazil HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 61: Brazil HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 62: Middle East HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 63: Middle East HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 64: Middle East HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 65: Africa HIV Drugs Market, Historic, 2015 – 2020, $ Million
  • Figure 66: Africa HIV Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 67: Africa HIV Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 68: Global HIV Drugs Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 69: Gilead Sciences, Inc. – Financial Performance, 2015 – 2019, $ Billion
  • Figure 70: GlaxoSmithKline Plc. – Financial Performance, 2015 – 2019, $ Billion
  • Figure 71: Johnson & Johnson (J&J) – Financial Performance, 2015 – 2019, $ Billion
  • Figure 72: Merck & Co. – Financial Performance, 2015-2019, $ Billion
  • Figure 73: Boehringer Ingelheim GmbH – Financial Performance, 2015 - 2019, $ Billion
Global Lung Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Kidney Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Interleukin Inhibitors Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Immunosuppressants Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Inhalation Sedatives Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Insulin Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cancer Monoclonal Antibodies Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Clinical Nutrition Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Dry Eye Medication Market - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous and Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment, Others) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Pharmaceutical Drugs Market - By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Musculoskeletal Drugs Market Global Briefing 2018
View Report
Respiratory Drugs Market Global Briefing 2018
View Report
Antisense And RNAi Therapeutics Market- By Technology (RNA Interference, Antisense RNA), By Route Of Administration (Intravenous injections, Intra Dermal injunctions, Other delivery methods), By Indication (Oncology, Cardiovascular device, Respiratory disorders, Neurological disorders, Infectious disease, Other diseases), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)